Health and Healthcare

Merck (MRK): More Trouble With Vioxx

R218533_855025A lot of people believe that Merck (MRK) knew a lot more about the dangers of its arthritis drug Vioxx than the company ever let on. Heart problems were apparently a by-product of using the treatment.

An affirmation of Merck’s possible guilt was the $4.85 billion that it paid to settle a number of Vioxx suits. But, the fun may not be over.

According to Reuters, "A long-term analysis of people who took the arthritis drug Vioxx confirms it doubles the risk of strokes and heart attacks." Merck will probably say it did not know much about that, but presumably it does road test its own drugs.

The suits over Vioxx seemed to be dying down. That is not going to continue.

Douglas A. McIntyre

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.